🤔 Looking for clinical answers about GU and the oncology field? Good news, COMMENT on this post with any questions you have, and @CParkMD of @Norton_Health will answer them in OncLive's #AskMeAnything series‼️   💥 We'll be responding live at #ESMO2026 - NOTHING is off the table!   Drop your questions in the comments section of this post by October 24‼️ #oncology #cancer

Subgroup analyses from RASolute 302 showed daraxonrasib maintained its OS benefit across RAS mutation subtypes #pancsm #oncology Dive into the latest pancreatic cancer data to emerge from the study: onclive.com/view/daraxonrasi…

🧬 What could a CLDN18.2-directed ADC offer patients with previously treated advanced gastric cancer? At @esmoESMO #ESMO26, phase 3 G-HOPE-001 results highlight the potential of arcotatug tavatecan. Read more: onclive.com/view/arcotatug-t… #oncology

Adjuvant giredestrant sustained physical functioning, role functioning, and HRQOL and was associated with sustained low AE bother vs SOC in ER+, HER2– early breast cancer, according to PROs from lidERA Breast Cancer. @myESMO #ESMO2026 #bcsm #oncology onclive.com/view/adjuvant-gi…

Data from the phase 3 ENERGIZE trial showed the addition of perioperative nivolumab to neoadjuvant chemo did not yield a statistically significant improvement in pCR rate or EFS vs neoadjuvant chemo alone in muscle-invasive bladder cancer #blcsm #oncology Dive into the @myESMO #ESMO26 data here: onclive.com/view/perioperati…

Trial medians don't capture how individual patients with urothelial carcinoma actually respond. Daniel Ari Landau, MD, Matthew D. Galsky, MD, and Misagh Karimi, MD on real-world data, ADCs, and FGFR3/HER2-targeted sequencing. Watch now: hubs.li/Q04x2R0X0 @MUSChealth @TischCancer @DrMKarimi @cityofhopeoc #UrothelialCarcinoma #PrecisionOncology #FGFR3

First-line maintenance in ES-SCLC has been an open question for years. Hossein Borghaei, DO, MS of Fox Chase Cancer Center walks through why the Phase 3 IMforte results with lurbinectedin plus atezolizumab matter for practice. Read the full analysis: hubs.li/Q04vJMGN0 @HosseinBorghaei @FoxChaseCancer#SCLC #ImmunoOncology #ClinicalTrials

Thank you to @RWinayak of @cityofhope for sharing insights from research on novel target expressions in renal cell carcinoma, being presented at @myESMO #ESMO26

Just in: Teclistamab monotherapy is now approved in the EU for relapsed/refractory multiple myeloma following at least 1 prior line of therapy #mmsm #oncology Read more: onclive.com/view/teclistamab…

We're being taken over! During #ESMO26, follow along as #oncology experts take over OncLive's social accounts and share exclusive insights from @myESMO in Madrid. Stay tuned all meeting for updates from @GhosnMd, @RWinayak, @benweinbergmd, and @maryam_lustberg

No matter which character you choose, OncLive is going to cover all of ESMO❗ As the conference begins today, we are ready to go with several team members on the ground in Madrid 🇪🇸 Check our site for real-time coverage: onclive.com/conference/esmo-… @myESMO #ESMO26 #oncology

🗣️ Kicking things off with Johanna S. Enke, MD of @UCLAHealthJCCC discussing a trial evaluating lutetium Lu 177 vipivotide tetraxetan in prostate cancer. More overage on our site! #ESMO26 @myESMO #pcsm #oncology

We’re here in Madrid, Spain, for the, you guessed it, annual #ESMO26 Congress. Over the next week we’ll be bringing you author insights, written coverage, and live discussion from the conference floor on the practice-changing data being presented with @CParkMD! Stay tuned for more 👀 #ESMO26 #GlobalOncology @myESMO

Poll Results: Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at #ESMO2026. @myESMO #lcsm #oncology Full recap ➡️: onclive.com/view/polls-revea…

Poll Recap: Readers share their opinions on some of the most talked-about gynecologic cancer abstracts and topics they’re looking forward to seeing at #ESMO2026. @myESMO #gyncsm #oncology Full story ➡️: onclive.com/view/poll-result…

WATCH: @Leia_N_MD, of @UCLAHealth, discusses the significance of the inclusion of brigatinib in the NCCN Clinical Practice Guidelines in Oncology for NF2-related schwannomatosis. #oncology Full video: onclive.com/view/dr-nghiemph…

🔬 GU cancer data to watch at #ESMO26: @MattGalsky and @PrafulRavi1 spotlight VOLGA, DASL-HiCaP, and key bladder cancer studies ahead of Madrid. Explore the preview: hubs.li/Q04C1F4l0 #GUOncology

With multiple therapies available for HER2+ mCRC, the challenge is finding eligible patients early in their disease course and choosing the optimal order of therapy. @MikeCusnir @dr_simkins @MDmanishshah @WeillCornell @MountSinaiMiami #crcsm #oncology onclive.com/view/her2-mcrc-t…